Innovent's therapeutic antibody portfolio will be combined with Bolt's ISAC technology to create the new cancer treatments.

Under the agreement, Innovent has the rights to all three programs in Greater China and retains an option to license global rights for one program, as well as rights for all territories except North America for another program.

Bolt retains the option to license global rights outside of Greater China for one program and North American rights for another program. Innovent is responsible for all R&D costs through clinical proof of concept, according to the companies.

Eli Lilly, Innovent expand immuno-oncology licensing
Eli Lilly and Innovent Biologics have agreed to a global expansion of their strategic alliance for Tyvyt (sintilimab injection), an anti-programmed cell...

Innovent, Roche partner on cell therapies, bispecific antibodies
Innovent Biologics has entered into a research and development collaboration with Roche for multiple cell therapies and bispecific antibodies.